Integrating HCV Testing and Treatment Into HIV Care: A Cohort Study of the HCV Care Cascade in Southwest China
Liver International · 2026-11 · 46 (11)
DOI: 10.1111/liv.70899 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Liver International, online erschienen am 30.09.2026. Verfasst von Minyang Xiao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Yunnan Center for Disease Control and Prevention (Yunnan Academy of Preventive Medicine), Kunming, China. Hauptthemen laut MEDLINE: HIV Infections, Hepatitis C, Antiviral Agents, Continuity of Patient Care. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Aim
Within the global population living with human immunodeficiency virus (HIV), achieving hepatitis C virus (HCV) micro‐elimination is a crucial public health strategy. We assessed the HCV care continuum among people with HIV (PWH) in Yunnan Province, China, a region with a historically high burden of both infections.
Methods
Linked data from provincial HIV and HCV surveillance systems (January 2022–June 2025) were analysed. An eight‐stage care continuum was constructed, ranging from anti‐HCV testing to sustained virologic response. Annual trends in the HCV care cascade were evaluated.
Results
Among 143 959 PWH, 90.3% underwent anti‐HCV testing. Of the 20 627 individuals who tested anti‐HCV positive, 67.3% were referred to the national surveillance system; among those reported, 84.7% tested positive for HCV RNA. Among individuals who were HCV RNA positive, 85.0% initiated direct‐acting antiviral treatment; the rate was 87.7% among those who were alive and retained in care. Those who completed post‐treatment assessment demonstrated a sustained virologic response rate of 99.1%. Between January 2022 and June 2025, the HCV RNA positivity rate among reported cases increased from 44.6% to 84.7%, with treatment initiation increasing from 77.5% to 85.0%. Subgroup analyses identified lower testing and treatment uptake among individuals lost to follow‐up, those who died, and certain demographics such as older adults and farmers.
Conclusions
Yunnan has made significant strides toward HCV micro‐elimination among PWH, demonstrating the feasibility of integrating HCV services into existing HIV care platforms. The findings may be useful to other resource‐limited settings seeking to achieve elimination targets established by the World Health Organization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yunnan Center for Disease Control and Prevention (Yunnan Academy of Preventive Medicine), Kunming, China.
- Yunnan Key Laboratory of Cross-Border Infectious Disease Control and Prevention and Novel Drug Development (Under Construction), Kunming, China.
- Yunnan Provincial Key Laboratory of Public Health and Biosafety, Kunming, China.
- Kunming Medical University, Kunming, China.
- National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
ORCID-Profile: Minyang Xiao, Zhi Zhao, Jian Li
Zitieren
APA
Xiao, M., Liu, C., Han, Y., Ma, Y., Guo, Y., Zhang, Z., Fu, L., Li, X., Zhang, X., Zhao, Z., Shi, Y., Jia, M., & Li, J. (2026). Integrating HCV Testing and Treatment Into HIV Care: A Cohort Study of the HCV Care Cascade in Southwest China. Liver International, 46(11). https://doi.org/10.1111/liv.70899
Vancouver
Xiao M, Liu C, Han Y, Ma Y, Guo Y, Zhang Z, et al. Integrating HCV Testing and Treatment Into HIV Care: A Cohort Study of the HCV Care Cascade in Southwest China. Liver International. 2026;46(11). doi:10.1111/liv.70899
BibTeX
@article{Xiao2026,
author = {Xiao, Minyang and Liu, Chuntao and Han, Yu and Ma, Yanling and Guo, Yan and Zhang, Zuyang and Fu, Liru and Li, Xuehua and Zhang, Xiujie and Zhao, Zhi and Shi, Yuhua and Jia, Manhong and Li, Jian},
title = {Integrating HCV Testing and Treatment Into HIV Care: A Cohort Study of the HCV Care Cascade in Southwest China},
journal = {Liver International},
year = {2026},
volume = {46},
number = {11},
doi = {10.1111/liv.70899}
}
EUVIMED